Patents by Inventor Liugen Li

Liugen Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS
    Publication number: 20220396587
    Abstract: Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Application
    Filed: January 22, 2020
    Publication date: December 15, 2022
    Inventors: Guozhi Tang, Dongbo Li, Liugen Li, Xianchan Zha, Wenming Chen, Shaomeng Wang, Chao-Yie Yang
  • Spirocyclic tetrahydroquinazolines
    Patent number: 11312724
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: April 26, 2022
    Inventors: Chao Li, Guozhi Tang, Jianyong Chen, Lingling Jiao, Liugen Li
  • SPIROCYCLIC TETRAHYDROQUINAZOLINES
    Publication number: 20210230174
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 29, 2021
    Inventors: CHAO LI, Guozhi Tang, Jianyong Chen, Lingling Jiao, Liugen Li